• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.S. gov awards CSL Biotherapies contract for influenza pandemic preparedness

U.S. gov awards CSL Biotherapies contract for influenza pandemic preparedness

September 14, 2012
CenterWatch Staff

CSL Biotherapies, a King of Prussia, Penn.-based subsidiary of CSL Limited, a manufacturers of influenza vaccines, has been awarded a contract by the HHS to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

The U.S. government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen.

Funding for the CSL Biotherapies contract is provided solely by the U.S. Department of Health and Human Services’ office of the assistant secretary for preparedness and response, biomedical advanced R&D authority. The contract has a maximum potential value of $1.5 billion if all optional activities are exercised over the duration of the contract.

"We are very pleased to again be working with the U.S. government on its pandemic preparedness efforts," said Dr. John Anderson, senior vice president of CSL Biotherapies. "CSL Biotherapies is committed to helping to protect the American public against the potential impact of an influenza pandemic. We are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. National Strategy for Pandemic Influenza."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing